News

A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.

The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s ODAC to examine data supporting the BLA seeking the agent’s approval for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.

Leading researchers from around the globe visited Fred Hutchinson Cancer Center to honor Dr E. Donnall Thomas and to discuss the future of transplantation, gene, and cellular therapies at the inaugural Dr E. Donnall Thomas Symposium.

Highly elevated levels of antidrug antibodies against atezolizumab were associated with poorer clinical outcomes for patients who received atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival improvements for advanced and metastatic disease.

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Capivasertib plus fulvestrant generated a statistically and clinically significant improvement in progression-free survival in select patients with hormone receptor–positive, HER2-low or -negative, locally advanced or metastatic breast cancer.

Cedars-Sinai cancer study shows novel strategy disrupts the difficult-to-treat tumor microenvironment, preventing cancer from spreading.

Misako Nagasaka, MD, PhD, discusses the various needs taletrectinib meets in the ROS1-positive population, initial efficacy data with the agent, and its impressive safety profile.

The combination of melphalan flufenamide and daratumumab plus hyaluronidase-fihj and dexamethasone improved progression-free survival over daratumumab and dexamethasone alone in select patients with relapsed/refractory multiple myeloma.

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.

Neil D. Gross, MD, FACS, discusses the current deficits in the treatment of patients with cutaneous squamous cell carcinoma in the curative setting and avenues for continued research generated by the primary analysis of the phase 2 trial examining neoadjuvant cemiplimab in this population.

The 4-drug combination of irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor elicited objective responses in almost half of patients with high-risk neuroblastoma.

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Jeannie Shen, MD, discussed the shifts in surgical practice for patients with breast cancer, the need for a multidisciplinary approach to optimize treatment for individual patients, and ongoing efforts at Huntington Hospital and Cedars-Sinai to increase awareness and improve care for these patients.

Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.

Jefferson Health’s Sidney Kimmel Cancer Center welcomes transdisciplinary population health researcher Terry Hyslop, PhD, as Co-leader of the Cancer Risk and Control Program.

Investigators hope to add RLY-4008, the first highly selective FGFR2 inhibitor, to the growing arsenal of treatment options for patients with cholangiocarcinoma.

Treatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with locally advanced nasopharyngeal carcinoma carrying at least 2 high risk factors.

Single-agent cemiplimab demonstrated safety and efficacy in patients with locally advanced or metastatic cutaneous squamous cell carcinoma who comprised group 6 of the phase 2 EMPOWER-CSCC-1 trial that was in line with what was previously reported in groups 1, 2, and 3 of the study.

Yuan Yuan, MD, PhD, discusses the role immune checkpoint inhibitors have played in the treatment of triple-negative breast cancer, ongoing efforts to investigate the role of immunotherapy in breast cancer, and the work Cedars-Sinai is conducting to promote breast cancer awareness.

Bevacizumab along with reirradiation extended progression-free survival compared with bevacizumab alone for patients with recurrent glioblastoma multiforme.

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.